

DRAFT

Appendix J Field Review Panel

Emizie Abbott, C.C.D.C. III
Executive Director
Cleveland Treatment Center, Inc.
Cleveland, Ohio

Patrick Abbott, M.D.
Center on Alcoholism, Substance Abuse
and Addiction
Albuquerque, New Mexico

Cynthia E. Aiken, L.P.A., M.S.
Executive Director
Narcotic Drug Treatment Center, Inc.
Anchorage, Alaska

Doug Allen, M.S.W.
Administrator
Planning Policy and Legislative Relations
Division of Alcohol and Substance Abuse
Department of Social & Health Services
State of Washington
Olympia, Washington

Leslie Amass, Ph.D.
Principal Investigator
Friends Research Institute, Inc.
Los Angeles, California

Robert E. Anderson
Director, Research and Program Applications
National Association of State Alcohol and
Drug Abuse Directors
Washington, District of Columbia

Gerard Armstrong
Deputy Director
Managed Care/Health and Revenue Services
Office of Alcoholism and Substance Abuse
Services
State of New York
New York, New York

Judith A. Arroyo, Ph.D.
Coordinator
Project COMBINE
Center on Alcoholism, Substance Abuse
and Addictions
University of New Mexico
Albuquerque, New Mexico

Candace L. Baker, M.A.C., ACSW
Director, Clinical Issues
The National Association of Alcoholism
and Drug Abuse Counselors
Arlington, Virginia

Doug Baker
Head, Adult Services Branch
Substance Abuse Services Section
Division of Mental Health, Developmental
Disabilities and Substance Abuse Services
State of North Carolina
Raleigh, North Carolina

Roxanne Baker
Director of Nor-Cal NAMA
Northern California National Alliance of
Methadone Advocates
Santa Cruz, California

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Steve Batki, M.D.

Professor and Director of Research
Department of Psychiatry
Upstate Medical University
Syracuse, New York

Jack Blaine, M.D.

Chief of Medications Research Grants Unit
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland

Ann Belk

Program Analyst
Office of Diversion Control
Drug Enforcement Administration
Washington, District of Columbia

Linda Brady, Ph.D.

Acting Chief of Molecular and Cellular
Neuroscience Research Branch
National Institute of Mental Health
National Institutes of Health
Bethesda, Maryland

Mark Beresky

Secretary/Treasurer
The Vermont Harm Reduction Coalition
Co-Director, The New England Chapter of the
National Alliance of Methadone Advocates
Putney, Vermont

Judy Braslow

Deputy Director for Policy
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Bruce J. Berg, M.D.

Vice President Medical Services
Magellan Behavioral Health
Bryn Mawr, Pennsylvania

Michael F. Brooks, D.O.

Medical Director
Saline Community Hospital
Greenbrook Recovery Center
Saline, Michigan

Robert Bick, M.A., SAC

Director
Champlain Drug and Alcohol Services
Howard Center for Human Services
Burlington, Vermont

Lawrence Brown, M.D., M.P.H.

Senior Vice President
Division of Medical Services Evaluation
and Research
Addiction Research Corporation
Brooklyn, New York

George Bigelow, Ph.D.

Professor
College on Problems of Drug Dependence
Behavioral Pharmacology Research Unit
Behavioral Biology Research Center
Johns Hopkins Bayview Campus
Baltimore, Maryland

Andrew Byrne, M.D., B.S.

Dependency Specialist, Medical Practitioner
Redfern, New South Wales
Australia

Anton C. Bizzell, M.D.

Medical Officer
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Jim Callahan, Ph.D.

Executive Vice President/Chief Executive
Officer
American Society of Addiction Medicine
Chevy Chase, Maryland

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

James C. Carleton, M.S.
Director, Narcotic Treatment Programs
CODAC Treatment Center, Inc.
Providence, Rhode Island

Louis Cataldie, M.D.
Medical Director
Office for Addictive Disorders
Department of Health and Hospitals
State of Louisiana
Baton Rouge, Louisiana

Susanne Caviness, Ph. D.
Captain, U.S. Public Health Service
Division of State and Community Assistance
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Richard Christensen, P.A., CAS
Vice President and Director of Medical
Services
Community Medical Services
Phoenix, Arizona

Darrell Christian, Ph.D.
Clinical Psychologist
New Leaf Treatment Center
Concord, California

Barbara Cimaglio
Administrator
Office of Alcohol and Drug Abuse Programs
Department of Human Services
State of Oregon
Salem, Oregon

H. Westley Clark, M.D., J.D., M.P.H.
CAS, FASAM
Director
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Denise Clayborn, Ph.D.
Human Services Adult and Opioid
Replacement Consultant
Office of Substance Abuse Services
Department of Mental Health, Mental
Retardation and Substance Abuse Services
Commonwealth of Virginia
Richmond, Virginia

Edward J. Cone, Ph.D.
Chief Executive Officer
Conechem Research
Severna Park, Maryland

Michael Couty, M.A.
Director
Division of Alcohol and Drug Abuse
Department of Mental Health
State of Missouri
Jefferson City, Missouri

Michael J. Crookston, M.D.
Psychiatrist, Chemical Dependency Services
LDS Hospital
Salt Lake City, Utah

Denise Curry
Chief of Liaison Unit
Office of Diversion Control
Drug Enforcement Administration
Washington, District of Columbia

Joy Davidoff
Coordinator of Addiction Medicine
Office of Alcoholism and Substance Abuse
Services
State of New York
Albany, New York

Peter A. DeMaria, Jr., M.D., FASAM
Associate Professor of Psychiatry and
Human Behavior
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Doug DeShong

Senior Product Manager, Suboxone
Schering
Kenilworth, Texas

Pamela Detrick, A.R.N.P.C., Ph.D.

Assistant Professor
School of Nursing
University of Miami
Miami, Florida

Herman I. Diesenhaus, Ph.D.

Buprenorphine Workgroup Coordinator
Office of Evaluation, Scientific Analysis and
Synthesis
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Alice Diorio

President
The Vermont Harm Reduction Coalition
Co-Director, The New England Chapter of the
National Alliance of Methadone Advocates
Putney, Vermont

Martin C. Doot, M.D.

Chief
Division of Addiction Medicine
Addiction Medicine/Family Practice
Lutheran General Hospital Advocate
Des Plaines, Illinois

Alfonzo Dorsey

Director of Quality Control
Substance Abuse Treatment and Recovery
Department of Social and Rehabilitative
Services
State of Kansas
Topeka, Kansas

Karen Downey, Ph.D.

Assistant Professor
Research Division on Substance Abuse
Department of Psychiatry and Behavioral
Neurosciences
Wayne State University
Detroit, Michigan

Michael Duffy, R.N., C.D.

Acting Assistant Secretary
Office of Alcohol and Drug Abuse
Department of Health and Hospitals
State of Louisiana
Baton Rouge, Louisiana

Joel Egerston

Special Assistant to the Director
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland

John P. Epling, M.D.

2303 Line Avenue
Shreveport, Louisiana

Virginia H. Ervin, B.S.N., CARN, COHN

Utilization Review Case Manager
Department of Alcohol and Other Drug Abuse
Services
State of South Carolina
Columbia, South Carolina

Garland S. Ferguson

Director, Division of Treatment Services
Bureau of Alcohol and Drug Abuse
Prevention
Department of Health
State of Arkansas
Freeway Medical Center
Little Rock, Arkansas

Michael Fingerhood, M.D.

Associate Professor of Medicine
Center for Chemical Dependence
Johns Hopkins Bayview Medical Center
Baltimore, Maryland

Gary Fisher, Ph.D.

Director and Professor
Center for the Application of Substance Abuse
Technologies
University of Nevada, Reno
Reno, Nevada

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Luceille Fleming
Director
Department of Alcohol and Drug Addiction
Services
State of Ohio
Columbus, Ohio

Paul Fudala, Ph.D.
Clinical Toxicologist
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Robert Fuller, M.D.
Director
Division of Clinical & Preventative Research
National Institute on Alcohol Abuse and
Alcoholism
National Institutes of Health
Rockville, Maryland

George R. Gilbert, J.D.
Director, Office of Policy Coordination
and Planning
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Daniel J. Glatt, M.D., M.P.H.
Fellow, Substance Abuse
San Francisco VA Medical Center
San Francisco, California

William Glatt, M.D.
Primary Care Physician
Internal Medicine and Addiction Medicine
South San Francisco, California

Angel A. González, M.D.
Senior Surgeon, U.S. Public Health Service
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Marc Gourevitch, M.D.
Medical Director
Division of Substance Abuse
Albert Einstein College of Medicine
Yeshiva University
Bronx, New York

Prakash L. Grover, Ph.D., M.P.H.
Senior Science Advisor
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Jack Gustafson
Executive Director
National Association of State Alcohol and
Drug Abuse Directors
Washington, District of Columbia

Susan W. Haikalis, LCSW
Director
HIV Services and Treatment Support
San Francisco AIDS Foundation
San Francisco, California

William F. Haning III, M.D., FASAM
Associate Dean
John A. Burns School of Medicine
University of Hawaii
Honolulu, Hawaii

Michael Harle
President/Executive Director
Gaudenzia, Inc.
Norristown, Pennsylvania

Dana Harlow, LISW, CCDC III-E
Manager
Department of Alcohol and Drug Addiction
Services
State of Ohio
Columbus, Ohio

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Reva Harris, M.B.A., B.S.

Fellow
Office of Congressman Charles Rangel
Washington, District of Columbia

John Harsany, Jr., M.D.

Medical Director
Riverside County Substance Abuse Program
Hemet, California

Dory Hector

State Methadone Authority
Division of Substance Abuse Services
Department of Mental Health and Mental
Retardation
State of Alabama
Montgomery, Alabama

Renata J. Henry

Director
Division of Alcoholism, Drug Abuse, and
Mental Health
Department of Health and Social Services
State of Delaware
New Castle, Delaware

James Herrera, M.A., NCC, LPCC

Senior Counselor
Center on Alcoholism, Substance Abuse,
and Addictions
University of New Mexico
Albuquerque, New Mexico

Edward J. Higgins, M.A.

Executive Director
Jersey Shore Addiction Services, Inc.
Asbury Park, New Jersey

John Hopper, M.D.

Medical Director
UPC Opiate Dependence Treatment
Detroit, Michigan

Ronald J. Hunsicker, D.Min., FACATA

President/Chief Executive Officer
National Association of Addiction Treatment
Providers
Lititz, Pennsylvania

Ray Hylton, M.S.N., R.N.

Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Jerome Jaffe, M.D.

Clinical Professor of Psychiatry
University of Maryland
Towson, Maryland

Donald R. Jasinski, M.D.

Chief
Center for Chemical Dependence
Johns Hopkins Bayview Medical Center
Baltimore, Maryland

Kimberly Johnson

Director
Office of Substance Abuse
State of Maine
Augusta, Maine

Rolley E. Johnson, Pharm.D.

Associate Professor
Department of Psychiatry and Behavioral
Sciences
Behavioral Pharmacology Research Unit
Johns Hopkins University School of Medicine
Baltimore, Maryland

Linda R. Wolf Jones, D.S.W.

Executive Director
Therapeutic Communities of America
Washington, District of Columbia

Herman Joseph, Ph.D.

Research Scientist
Office of Alcoholism and Substance Abuse
Services
State of New York
New York, New York

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

George Kanuck
Public Health Analyst
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Janice F. Kauffman, R.N., M.P.H., CAS
Director, Substance Abuse Treatment Services
North Charles, Inc.
Director, Addiction Psychiatry Service
Brigham and Women's Hospital
Assistant Professor of Psychiatry
Harvard Medical School
Somerville, Massachusetts

Chris Kelly
President, DC-Chapter
Advocates for Recovery Through Medicine
Washington, District of Columbia

Maureen Kerrigan, J.D.
Policy and Legislative Analyst
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Amesbury, Massachusetts

Steven Kipnis, M.D., FACP
Medical Director
Blaisdell Addiction Treatment Center
Orangeburg, New York

Monika Koch, M.D.
Addiction Psychiatrist
Friends Research Associates
Berkeley, California

Thomas R. Kosten, M.D.
Professor
Department of Psychiatry
Yale University
American Academy of Addiction Psychiatry
VA Connecticut Healthcare System
West Haven, Connecticut

Ottis L. Layne, M.D.
Medical Director
Emergency Department
Hill County Memorial Hospital
Fredericksburg, Texas

Ira Lubell, M.D., M.P.M.
Medical Director
Santa Clara Valley Medical Center
San Jose, California

Robert Lubran, M.S., M.P.A.
Director
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

James W. Luckey, Ph.D.
Associate Director
Substance Abuse Research Group
Westat
Rockville, Maryland

Stephen Magura, Ph.D., CSW
Director
Institute for Treatment and Services Research
National Development and Research
Institutes
New York, New York

Kathleen Masis, M.D.
Medical Officer for Chemical Dependency
Office of Health Care
Billings Area Indian Health Service
U.S. Department of Health and
Human Services
Billings, Montana

Stephen S. Mason
Director
Office of Behavioral Health Services
Division of Alcoholism and Drug Abuse
Department of Health and Human Resources
State of West Virginia
Charleston, West Virginia

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Mary Mayhew
Congressional Division
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland

Philip S. McCullough
Director
Bureau of Substance Abuse Services
Division of Supportive Living
Department of Health and Family Services
State of Wisconsin
Madison, Wisconsin

John J. McGovern, CSW
Director
Clinical Services
HELP/Project Samaritan, Inc.
Bronx, New York

Kathleen McGowan, J.D.
Legislative Assistant
Office of Senator Moynihan
Washington, District of Columbia

Paul McLaughlin
Executive Director
Hartford Dispensary
Hartford, Connecticut

John Mendelson, M.D.
Associate Clinical Professor Psychiatry and
Medicine
Drug Dependence Research Center
University of California at San Francisco
San Francisco, California

Robert Miller, M.A.
Operations Manager
Office of Alcohol and Drug Abuse Programs
Department of Human Services
State of Oregon
Salem, Oregon

Sharon Morello, R.N., B.S.N.
Nursing Care Evaluator
Division of Substance Abuse
Department of Mental Health, Retardation
and Hospitals
State of Rhode Island
Cranston, Rhode Island

Don Myers
Treatment Field Manager/State Methadone
Authority
Alcohol and Drug Abuse Division
Department of Human Services
State of Colorado
Denver, Colorado

David K. Nace, M.D.
Senior Vice President
United Behavioral Health
Philadelphia, Pennsylvania

**Madeline A. Naegle, Ph.D., R.N., C.S.,
FAAN**
Associate Professor
Division of Nursing
School of Education
New York University
New York, New York

Susan F. Neshin, M.D.
Medical Director
Jersey Shore Addiction Service, Inc.
Asbury Park, New Jersey

Thomas Nicholson, Ph.D., M.P.H., M.A.Ed.
Professor
Department of Public Health
Western Kentucky University
Bowling Green, Kentucky

Edward V. Nunes, M.D.
Research Psychiatrist and Assistant Professor
of Clinical Psychiatry
New York State Psychiatric Institute
New York, New York

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

David Ockert, D.S.W.

Executive Director
Parallax Center
New York, New York

Kerry O'Neil

Chief of Treatment Services
Division of Substance Abuse
Department of Mental Health, Retardation
and Hospitals
State of Rhode Island
Cranston, Rhode Island

Patricia Isbell Ordorica, M.D.

James A. Haley Veterans' Hospital
Tampa, Florida

Mark Parrino, M.P.A.

President
American Methadone Treatment Association
New York City, New York

David Pating, M.D.

Medical Director
Chemical Dependency Recovery Program
Kaiser San Francisco
San Francisco, California

J. Thomas Payte, M.D.

Medical Director
Drug Dependence Associates
San Antonio, Texas

Lillian Pickup

Administrator
Department of Alcoholism and Substance
Abuse
State of Illinois
Chicago, Illinois

Deborah Powers

State Methadone Authority
Bureau of Substance Abuse Services
State of Wisconsin
Madison, Wisconsin

Sandi Record

Director
Treatment, Prevention and Program
Department
Office for Addiction Disorder, Alcohol and
Drug Abuse
State of Louisiana
Baton Rouge, Louisiana

Nicholas Reuter, M.P.H.

Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Michael Rizzi

Deputy Director
CODAC Treatment Centers
Cranston, Rhode Island

Diedre Roach, M.D.

Administrator
Alcohol Prevention and Recovery
Administration
District of Columbia Department of Health
Washington, District of Columbia

Barbara T. Roberts, Ph.D.

Policy Analyst
White House Office of National Drug
Control Policy
Washington, District of Columbia

June Ross, B.S., ICADC

Executive Director
12 12, Inc.
Tulsa, Oklahoma

Pedro Ruiz, M.D.

Mental Sciences Institute
University of Texas
Houston, Texas

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Richard Saitz, M.D., M.P.H.

Associate Professor of Medicine
Clinical Addiction Research and Education
(CARE) Unit
Section of General Internal Medicine
Boston Medical Center and Boston University
School of Medicine
Boston, Massachusetts

Jeff Samet, M.D., M.A., M.P.H.

Associate Professor
Boston University School of Medicine
Boston, Massachusetts

Sidney Schnoll, M.D., Ph.D.

Professor and Chairman
Addiction Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, Virginia

Mary Schumacher

Director
Behavioral Health Services Division
Department of Health
State of New Mexico
Santa Fe, New Mexico

Ian A. Shaffer, M.D.

Principal
Ian A. Shaffer & Associates, L.L.C.
Reston, Virginia

Steve Shoptow, Ph.D.

Integrated Substance Abuse Programs
University of California at Los Angeles
Los Angeles, California

Larry Siegel, M.D.

Senior Deputy Director
Administrator
Addiction Prevention and Recovery
Administration
District of Columbia Department of Health
Washington, District of Columbia

Cynthia L. Spencer, D.O.

Medical Director
Substance Abuse Services
Lansing, Michigan

George Stavros, M.D.

Medical Director
Community Medical Services
Phoenix, Arizona

Richard T. Suchinsky, M.D.

Associate Chief for Addictive Disorders
Mental Health and Behavioral Sciences
Service
U.S. Department of Veteran Affairs
Washington, District of Columbia

Kenneth Sunamoto, M.D.

Medical Director
Drug Addiction Services of Hawaii, Inc.
Honolulu, Hawaii

Karen Tannert, R.Ph.

Chief Pharmacist
Drugs and Medical Devices Division
Department of Health
State of Texas
Austin, Texas

Tony Tommasello, Ph.D.

Department of Pharmacy Practice and
Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Alan Trachtenberg, M.D.

Medical Director
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

DRAFT

Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

April 23, 2004

Donald Weinbaum
Coordinator
Criminal Justice and Block Grant
Planning Unit
Division of Addiction Services
Department of Health
State of New Jersey
Trenton, New Jersey

Richard Weisskopf
Manager
Methadone Treatment Services
Office of Alcoholism and Substance Abuse
Department of Human Services
State of Illinois
Chicago, Illinois

Donald R. Wesson, M.D.
Consultant, CNS Medications Development
Oakland, California

Charles L. Whitfield, M.D.
Private Practice of Addiction Medicine
Atlanta, Georgia

Cheryl Williams
Director
Division of Drug and Alcohol Program
Licensure
Department of Health
State of Pennsylvania
Harrisburg, Pennsylvania

Jaslene Williams
Assistant Director
Division of Mental Health
U.S. Virgin Islands
Christiansted, Virgin Islands

Janet Wood
Director
Alcohol and Drug Abuse Division
Department of Human Services
State of Colorado
Denver, Colorado

William Wood, M.D.
Chief Medical Officer
ValueOptions
Falls Church, Virginia

George E. Woody, M.D.
Professor
Department of Psychiatry
Treatment Research Institute
Philadelphia, Pennsylvania

Richard Yoast, Ph.D.
Director
Office of Alcohol
American Medical Association
Chicago, Illinois

Leah Young
Public Affairs Specialist
Office of Communication and External
Liaison
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, Maryland

Edward Zborower
Program Representative/State Methadone
Authority
Bureau of Substance Abuse and General
Mental Health
Department of Health Services
State of Arizona
Phoenix, Arizona

Steve Zukin
Division of Treatment Research
and Development
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland